XENON PHARMACEUTICALS INC. Cash and Cash Equivalents, Period Increase (Decrease)
XENON PHARMACEUTICALS INC. (XENE) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$30.68 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-06.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-08-06
- XENON PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$15.11M, a 149.96% decline year-over-year.
- XENON PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$15.57M.
- XENON PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$20.21M, a 448.53% decline year-over-year.
- XENON PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $40.53M.
- XENON PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $47.27M, a 1293.93% increase from fiscal 2017.
- XENON PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $3.39M.
- XENON PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$41.56M.
- XENON PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$13.38M, a 139.25% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-06-30 | -$15.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$30.68M 10-Q · filed 2019-08-06 | -$50.89M derived: sum of 3 quarters · filed 2019-08-06 | -$10.36M derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | -$15.57M 10-Q · filed 2019-05-07 | -$35.78M derived: sum of 2 quarters · filed 2019-05-07 | $4.75M derived: sum of 3 quarters · filed 2019-05-07 | $34.98M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-12-31 | -$20.21M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $20.32M derived: sum of 2 quarters · filed 2019-03-06 | $50.55M derived: sum of 3 quarters · filed 2019-08-06 | $47.27M 10-K · filed 2019-03-06 |
| 2018-09-30 | $40.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $70.76M derived: sum of 2 quarters · filed 2019-08-06 | $67.48M 10-Q · filed 2018-11-06 | $73.27M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-06-30 | $30.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $26.95M 10-Q · filed 2019-08-06 | $32.75M derived: sum of 3 quarters · filed 2019-08-06 | $24.34M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | -$3.29M 10-Q · filed 2019-05-07 | $2.51M derived: sum of 2 quarters · filed 2019-05-07 | -$5.89M derived: sum of 3 quarters · filed 2019-05-07 | -$2.96M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | -$2.60M derived: sum of 2 quarters · filed 2019-03-06 | $326.00K derived: sum of 3 quarters · filed 2019-03-06 | $3.39M 10-K · filed 2019-03-06 |
| 2017-09-30 | -$8.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$5.47M derived: sum of 2 quarters · filed 2018-11-06 | -$2.41M 10-Q · filed 2018-11-06 | -$39.45M derived: sum of 4 quarters · filed 2018-11-06 |
| 2017-06-30 | $2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $6.00M 10-Q · filed 2018-08-07 | -$31.05M derived: sum of 3 quarters · filed 2018-08-07 | -$12.12M derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-03-31 | $3.06M 10-Q · filed 2018-05-08 | -$33.98M derived: sum of 2 quarters · filed 2018-05-08 | -$15.05M derived: sum of 3 quarters · filed 2018-05-08 | -$35.90M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | -$37.04M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$18.11M derived: sum of 2 quarters · filed 2018-03-07 | -$38.97M derived: sum of 3 quarters · filed 2018-03-07 | -$41.56M 10-K · filed 2018-03-07 |
| 2016-09-30 | $18.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$1.93M derived: sum of 2 quarters · filed 2017-11-07 | -$4.52M 10-Q · filed 2017-11-07 | -$11.33M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | -$20.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$23.44M 10-Q · filed 2017-08-03 | -$30.26M derived: sum of 3 quarters · filed 2018-03-07 | -$29.14M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | -$2.59M 10-Q · filed 2017-05-09 | -$9.40M derived: sum of 2 quarters · filed 2018-03-07 | -$8.28M derived: sum of 3 quarters · filed 2018-03-07 | -$9.85M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | -$6.82M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$5.70M derived: sum of 2 quarters · filed 2018-03-07 | -$7.27M derived: sum of 3 quarters · filed 2018-03-07 | -$13.38M 10-K · filed 2018-03-07 |
| 2015-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$448.00K derived: sum of 2 quarters · filed 2016-11-03 | -$6.56M 10-Q · filed 2016-11-03 | $31.74M derived: sum of 4 quarters · filed 2017-03-08 |
| 2015-06-30 | -$1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$7.68M 10-Q · filed 2016-08-03 | $30.61M derived: sum of 3 quarters · filed 2017-03-08 | $29.26M derived: sum of 4 quarters · filed 2017-03-08 |
| 2015-03-31 | -$6.11M 10-Q · filed 2016-05-10 | $32.19M derived: sum of 2 quarters · filed 2017-03-08 | $30.83M derived: sum of 3 quarters · filed 2017-03-08 | $30.97M derived: sum of 4 quarters · filed 2017-03-08 |
| 2014-12-31 | $38.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $36.94M derived: sum of 2 quarters · filed 2017-03-08 | $37.08M derived: sum of 3 quarters · filed 2017-03-08 | $34.08M 10-K · filed 2017-03-08 |
| 2014-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$1.22M derived: sum of 2 quarters · filed 2015-11-10 | -$4.22M 10-Q · filed 2015-11-10 | -$9.88M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-06-30 | $140.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2015-08-13 | -$2.86M 10-Q · filed 2015-08-13 | -$8.52M derived: sum of 3 quarters · filed 2016-03-08 | |
| 2014-03-31 | -$3.00M 10-Q/A · filed 2015-08-13 | -$8.66M derived: sum of 2 quarters · filed 2016-03-08 | ||
| 2013-12-31 | -$5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | -$22.21M 10-K · filed 2016-03-08 | ||
| 2013-09-30 | -$16.55M 10-Q · filed 2014-12-15 | |||
| 2012-12-31 | $46.23M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |